05:08:36 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-28 Kvartalsrapport 2024-Q3
2024-08-27 Kvartalsrapport 2024-Q2
2024-06-20 Ordinarie utdelning AXIC A 0.00 SEK
2024-06-19 Årsstämma 2024
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-06 Extra Bolagsstämma 2024
2024-03-05 Bokslutskommuniké 2023
2023-11-22 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-06-19 Ordinarie utdelning AXIC A 0.00 SEK
2023-06-16 Årsstämma 2023
2023-05-24 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-01 Ordinarie utdelning AXIC A 0.00 SEK
2022-05-31 Årsstämma 2022
2022-05-24 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-31 Kvartalsrapport 2021-Q2
2021-05-31 Ordinarie utdelning AXIC A 0.00 SEK
2021-05-28 Årsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-02-24 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning AXIC A 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-29 Ordinarie utdelning AXIC A 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-23 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-29 Kvartalsrapport 2018-Q2
2018-06-01 Ordinarie utdelning AXIC A 0.00 SEK
2018-05-31 Årsstämma 2018
2018-05-15 Kvartalsrapport 2018-Q1
2018-02-27 Bokslutskommuniké 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-06-01 Ordinarie utdelning AXIC A 0.00 SEK
2017-05-31 Årsstämma 2017
2017-05-31 Kvartalsrapport 2017-Q1
2017-05-24 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-11-24 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-24 Ordinarie utdelning AXIC A 0.00 SEK
2016-05-23 Årsstämma 2016
2016-05-19 Kvartalsrapport 2016-Q1
2016-02-25 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-29 Ordinarie utdelning AXIC A 0.00 SEK
2015-05-28 Årsstämma 2015
2015-05-25 Kvartalsrapport 2015-Q1
2015-02-26 Bokslutskommuniké 2014
2014-11-24 Kvartalsrapport 2014-Q3
2014-08-28 Kvartalsrapport 2014-Q2
2014-05-22 Årsstämma 2014
2014-05-22 Kvartalsrapport 2014-Q1
2014-02-28 Bokslutskommuniké 2013
2013-11-29 Kvartalsrapport 2013-Q3
2013-08-26 Kvartalsrapport 2013-Q2
2013-06-28 Split AXIC A 4:1
2013-05-30 Kvartalsrapport 2013-Q1
2013-05-21 Ordinarie utdelning AXIC A 0.00 SEK
2013-05-20 Årsstämma 2013
2013-02-28 Bokslutskommuniké 2012
2012-11-26 Kvartalsrapport 2012-Q3
2012-08-30 Kvartalsrapport 2012-Q2
2012-05-28 Kvartalsrapport 2012-Q1
2012-05-17 Ordinarie utdelning AXIC A 0.00 SEK
2012-05-16 Årsstämma 2012
2012-02-29 Bokslutskommuniké 2011
2011-11-28 Kvartalsrapport 2011-Q3
2011-08-30 Kvartalsrapport 2011-Q2
2011-05-30 Kvartalsrapport 2011-Q1
2011-05-10 Ordinarie utdelning AXIC A 0.00 SEK
2011-05-09 Årsstämma 2011
2011-02-25 Bokslutskommuniké 2010
2010-05-11 Ordinarie utdelning AXIC A 0.00 SEK

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorMaterial
IndustriPlast, kemikalier & fetter
aXichem är verksamt inom industriell bioteknik. Bolaget utvecklar, patenterar och marknadsför industrikemikalier. Bolaget arbetar framförallt med Fenylcapsaicin, en naturanalog syntetisk capsaicin med tillämpningar inom en mängd olika områden, såsom inom den marina sektorn, bland skadedjursbekämpning i skogs-och jordbruk, samt bland enskilda farmaceutiska arbetsområden. Verksamhet drivs på global nivå, med huvudkontoret i Malmö.
2024-01-30 15:00:00

aXichem AB (https://www.axichem.com/) (publ), (aXichem), a developer of innovative natural analogue ingredients for the nutraceutical market, is excited to announce the company has signed a Letter of Intent (LOI) with Silvaco A/S (https://www.silvaco.eu/profile), a key player in the nutraceutical, pharmaceutical, food, feed, and cosmetics industries in Scandinavia. This LOI marks the beginning of a promising collaboration aimed at introducing aXivite (https://axivite.com/), into the Scandinavian dietary supplement market.

Silvaco A/S is a well-established, dynamic and fast-growing company, specializing in sourcing and marketing quality ingredients and raw materials for various industries. Silvaco is based in Denmark and has a strong footprint in the Scandinavian region.

"The LOI outlines the collaborative approach to commercialize aXivite, aXichem's proprietary material known for its beneficial properties in weight loss, sports nutrition, sleep aid, and gut health. Silvaco's established market presence and expertise will play a crucial role in introducing aXivite to potential customers in Scandinavia in these sectors", says Lucas Altepost, VP and VP of Sales and Marketing at aXichem.

"We look forward to a fruitful collaboration with aXichem and are excited about the opportunities this partnership will bring to the Scandinavian nutraceutical market. The partnership is expected to leverage Silvaco's extensive network and deep market knowledge, aligning perfectly with aXichem's commitment to finding the right partners in local markets", says Henrik Petersen, CEO of Silvaco.

The total market for nutrition products in the Nordic region (Denmark, Finland, Norway and Sweden) reached almost 800 million Euro in 2020 according to Euromonitor. The documented effects of aXivite and aXichem's targeted market segments are well in line with the key trends that will drive the market during the coming years as presented in the report Dietary Supplement Market Outlook from 2024 to 2034 (https://www.futuremarketinsights.com/reports/dietary-supplements-market) by Futuremarketinsights.com, such as:
  • Increasing demand for probiotics and prebiotics to enhance one's digestive health.
  • Growing demand for sports nutrition supplements amid surging need to improve the endurance and strength of bodybuilders & athletes.

For more information about Silvaco A/S, please visit www.silvaco.eu.

About phenylcapsaicin and aXivite
aXichem's proprietary molecule, phenylcapsaicin, combines the naturally occurring phenyl group with capsaicin, connected by a triple bond. The result is an innovative natural analog capsaicin with high purity, which in several studies has been shown to have the same health-promoting properties, as well as some unique benefits, as natural capsaicin. Phenylcapsaicin is approved under Novel Food in the EU and GRAS Food in the USA and is marketed for dietary supplements and functional foods under the brand name aXivite.

The information was submitted, through the care of the contact person below, for publication on
30 January 2024, at 15:00 CET.